Effects of atropine treatment on in vitro and in vivo binding of 4-[125I]-dexetimide to central and myocardial muscarinic receptors

Yoshihiro Uno, Kaname Matsumura, Ursula Scheffel, Alan A. Wilson, Robert F Dannals, Henry N. Wagner

Research output: Contribution to journalArticle

Abstract

Upregulation of muscarinic cholinergic receptors (mAChR) after chronic atropine treatment has been described previously. The present study was designed to evaluate 4-iodine-125 dexetimide as an agent to determine changes in the number of mAChR. Rats were injected subcutaneously with atropine (500 mg/kg) either once or chronically, once daily for 10 days, and sacrificed 24 h later. In vitro binding assays with 4-[125I]-dexetimide showed significant increases in the number of mAChR in cerebra (21%) and ventricles (45%) after chronic atropine treatment but not after acute treatment. The affinity of binding to cerebral and ventrical mAChR declined after acute and chronic atropine treatment. In vivo studies were carried out involving intravenous injection of 4-[125I]-dexetimide 24 h after atropine treatment. Binding was markedly reduced in the brain and heart. Upregulation of mAChR, as seen in in vitro studies, could not be observed because of the remaining atropine. Occupancy of mAChR by atropine persisted as long as 7 days after one dose. The results of these studies indicate that 4-[125I]-dexetimide binding reflects the effects of atropine on central and peripheral muscarinic cholinergic receptors in vitro and in vivo.

Original languageEnglish (US)
Pages (from-to)447-452
Number of pages6
JournalEuropean Journal Of Nuclear Medicine
Volume18
Issue number7
DOIs
StatePublished - Jul 1991

Fingerprint

Dexetimide
Muscarinic Receptors
Atropine
Cholinergic Receptors
Therapeutics
Up-Regulation
In Vitro Techniques
Cerebrum
Intravenous Injections
Iodine

Keywords

  • 4-Iodine-125 dextimide
  • Atropine treatment
  • Central and myocardial mAChR
  • In vitro and in vivo binding

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Effects of atropine treatment on in vitro and in vivo binding of 4-[125I]-dexetimide to central and myocardial muscarinic receptors. / Uno, Yoshihiro; Matsumura, Kaname; Scheffel, Ursula; Wilson, Alan A.; Dannals, Robert F; Wagner, Henry N.

In: European Journal Of Nuclear Medicine, Vol. 18, No. 7, 07.1991, p. 447-452.

Research output: Contribution to journalArticle

Uno, Yoshihiro ; Matsumura, Kaname ; Scheffel, Ursula ; Wilson, Alan A. ; Dannals, Robert F ; Wagner, Henry N. / Effects of atropine treatment on in vitro and in vivo binding of 4-[125I]-dexetimide to central and myocardial muscarinic receptors. In: European Journal Of Nuclear Medicine. 1991 ; Vol. 18, No. 7. pp. 447-452.
@article{c7a91cbae4d644b2a852fb1aa0fa6f00,
title = "Effects of atropine treatment on in vitro and in vivo binding of 4-[125I]-dexetimide to central and myocardial muscarinic receptors",
abstract = "Upregulation of muscarinic cholinergic receptors (mAChR) after chronic atropine treatment has been described previously. The present study was designed to evaluate 4-iodine-125 dexetimide as an agent to determine changes in the number of mAChR. Rats were injected subcutaneously with atropine (500 mg/kg) either once or chronically, once daily for 10 days, and sacrificed 24 h later. In vitro binding assays with 4-[125I]-dexetimide showed significant increases in the number of mAChR in cerebra (21{\%}) and ventricles (45{\%}) after chronic atropine treatment but not after acute treatment. The affinity of binding to cerebral and ventrical mAChR declined after acute and chronic atropine treatment. In vivo studies were carried out involving intravenous injection of 4-[125I]-dexetimide 24 h after atropine treatment. Binding was markedly reduced in the brain and heart. Upregulation of mAChR, as seen in in vitro studies, could not be observed because of the remaining atropine. Occupancy of mAChR by atropine persisted as long as 7 days after one dose. The results of these studies indicate that 4-[125I]-dexetimide binding reflects the effects of atropine on central and peripheral muscarinic cholinergic receptors in vitro and in vivo.",
keywords = "4-Iodine-125 dextimide, Atropine treatment, Central and myocardial mAChR, In vitro and in vivo binding",
author = "Yoshihiro Uno and Kaname Matsumura and Ursula Scheffel and Wilson, {Alan A.} and Dannals, {Robert F} and Wagner, {Henry N.}",
year = "1991",
month = "7",
doi = "10.1007/BF00181282",
language = "English (US)",
volume = "18",
pages = "447--452",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Effects of atropine treatment on in vitro and in vivo binding of 4-[125I]-dexetimide to central and myocardial muscarinic receptors

AU - Uno, Yoshihiro

AU - Matsumura, Kaname

AU - Scheffel, Ursula

AU - Wilson, Alan A.

AU - Dannals, Robert F

AU - Wagner, Henry N.

PY - 1991/7

Y1 - 1991/7

N2 - Upregulation of muscarinic cholinergic receptors (mAChR) after chronic atropine treatment has been described previously. The present study was designed to evaluate 4-iodine-125 dexetimide as an agent to determine changes in the number of mAChR. Rats were injected subcutaneously with atropine (500 mg/kg) either once or chronically, once daily for 10 days, and sacrificed 24 h later. In vitro binding assays with 4-[125I]-dexetimide showed significant increases in the number of mAChR in cerebra (21%) and ventricles (45%) after chronic atropine treatment but not after acute treatment. The affinity of binding to cerebral and ventrical mAChR declined after acute and chronic atropine treatment. In vivo studies were carried out involving intravenous injection of 4-[125I]-dexetimide 24 h after atropine treatment. Binding was markedly reduced in the brain and heart. Upregulation of mAChR, as seen in in vitro studies, could not be observed because of the remaining atropine. Occupancy of mAChR by atropine persisted as long as 7 days after one dose. The results of these studies indicate that 4-[125I]-dexetimide binding reflects the effects of atropine on central and peripheral muscarinic cholinergic receptors in vitro and in vivo.

AB - Upregulation of muscarinic cholinergic receptors (mAChR) after chronic atropine treatment has been described previously. The present study was designed to evaluate 4-iodine-125 dexetimide as an agent to determine changes in the number of mAChR. Rats were injected subcutaneously with atropine (500 mg/kg) either once or chronically, once daily for 10 days, and sacrificed 24 h later. In vitro binding assays with 4-[125I]-dexetimide showed significant increases in the number of mAChR in cerebra (21%) and ventricles (45%) after chronic atropine treatment but not after acute treatment. The affinity of binding to cerebral and ventrical mAChR declined after acute and chronic atropine treatment. In vivo studies were carried out involving intravenous injection of 4-[125I]-dexetimide 24 h after atropine treatment. Binding was markedly reduced in the brain and heart. Upregulation of mAChR, as seen in in vitro studies, could not be observed because of the remaining atropine. Occupancy of mAChR by atropine persisted as long as 7 days after one dose. The results of these studies indicate that 4-[125I]-dexetimide binding reflects the effects of atropine on central and peripheral muscarinic cholinergic receptors in vitro and in vivo.

KW - 4-Iodine-125 dextimide

KW - Atropine treatment

KW - Central and myocardial mAChR

KW - In vitro and in vivo binding

UR - http://www.scopus.com/inward/record.url?scp=0025766377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025766377&partnerID=8YFLogxK

U2 - 10.1007/BF00181282

DO - 10.1007/BF00181282

M3 - Article

C2 - 1915471

AN - SCOPUS:0025766377

VL - 18

SP - 447

EP - 452

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 7

ER -